earnings
confidence high
sentiment positive
materiality 0.75
Prestige Q3 FY2025 EPS $1.22 (+15% YoY); raises FY25 adjusted EPS outlook to ~$4.50
Prestige Consumer Healthcare Inc.
2025-Q3 EPS
reported $3.28
vs consensus $0.98
▲ beat
(+234.7%)
- Q3 revenues $290.3M (+2.7% YoY); record quarterly sales and EPS.
- Diluted EPS $1.22 vs $1.06 prior year; net income $61.0M vs $53.0M.
- Raises FY25 adjusted EPS outlook to ~$4.50 from $4.40-$4.46; FCF ≥$240M reaffirmed.
- International OTC segment grew 11.3% (8.3% ex-FX); North American OTC +1.0%.
- Leverage reduced to 2.5x; repurchased 0.6M shares for ~$40.2M YTD.